U-CHANGE Project: a multidimensional consensus on how clinicians, patients and caregivers may approach together the new urothelial cancer scenario
暂无分享,去创建一个
P. Bruzzi | M. Brunelli | R. Iacovelli | V. Baldazzi | S. Bracarda | G. Colombo | A. Marinozzi | D. Croce | G. Conti | P. Zucali | G. Pappagallo | F. Remiddi | Stefano Remiddi | A. Gernone | E. O. Salé | E. Fiorini | F. Ferrante | D. Lenzi | L. Magenta | Francesco Diomede | Federico Mereta | Irma D’Aria | Danilo Magliano | Monica Liberatori | Daniel Cantu | Simone Eandi
[1] Xinyu Zheng,et al. A multicentre single arm phase 2 trial of neoadjuvant pyrotinib and letrozole plus dalpiciclib for triple-positive breast cancer , 2022, Nature Communications.
[2] S. Srinivas,et al. Study EV-103 Cohort H: Antitumor activity of neoadjuvant treatment with enfortumab vedotin monotherapy in patients (pts) with muscle invasive bladder cancer (MIBC) who are cisplatin-ineligible. , 2022, Journal of Clinical Oncology.
[3] H. Seo,et al. Fibroblast Growth Factor Inhibitors for Treating Locally Advanced/Metastatic Bladder Urothelial Carcinomas via Dual Targeting of Tumor-Specific Oncogenic Signaling and the Tumor Immune Microenvironment , 2021, International journal of molecular sciences.
[4] D. West,et al. 28481 Risk for nonmelanoma second primary malignancy in malignant melanoma survivors: A nationwide report from the National Cancer Institute Surveillance, Epidemiology, and End Results program , 2021 .
[5] T. Powles,et al. Enfortumab Vedotin in Advanced Urothelial Carcinoma. Reply. , 2021, New England Journal of Medicine.
[6] M. Harrison,et al. Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial. , 2021, The Lancet. Oncology.
[7] N. Agarwal,et al. TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] K. Smoyer,et al. Epidemiology and treatment patterns for locally advanced or metastatic urothelial carcinoma: a systematic literature review and gap analysis , 2020, Journal of managed care & specialty pharmacy.
[9] T. Powles,et al. 1O Clinical outcomes in post-operative ctDNA-positive muscle-invasive urothelial carcinoma (MIUC) patients after atezolizumab adjuvant therapy , 2020 .
[10] A. Grothey,et al. Establishment of a Molecular Tumor Board (MTB) and Uptake of Recommendations in a Community Setting , 2020, Journal of personalized medicine.
[11] N. Vasdev,et al. Urinary biomarkers in bladder cancer: A review of the current landscape and future directions. , 2020, Urologic oncology.
[12] M. Milowsky,et al. Study EV-103: Preliminary durability results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma. , 2020 .
[13] P. Giannatempo,et al. Epidemiology and unmet needs of bladder cancer in Italy: a critical review. , 2020, Minerva urologica e nefrologica = The Italian journal of urology and nephrology.
[14] M. Babjuk,et al. EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort†: Under the Auspices of the EAU-ESMO Guidelines Committees. , 2019, European urology.
[15] E. Philip,et al. Distress and Quality of Life Among Patients with Advanced Genitourinary Cancers. , 2019, European urology focus.
[16] R. Huddart,et al. Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. , 2019, The New England journal of medicine.
[17] Pranav Sharma,et al. Mental health implications in bladder cancer patients: A review. , 2019, Urologic oncology.
[18] C. Stief,et al. Health-related quality of life after radical cystectomy and ileal orthotopic neobladder: effect of detailed continence outcomes , 2019, World Journal of Urology.
[19] L. Kiemeney,et al. Epidemiology of Bladder Cancer: A Systematic Review and Contemporary Update of Risk Factors in 2018. , 2018, European urology.
[20] H. Woodrow,et al. : A Review of the , 2018 .
[21] Steven J. M. Jones,et al. Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer , 2017, Cell.
[22] F. Montorsi,et al. Cost of illness of urothelial bladder cancer in Italy , 2017, ClinicoEconomics and outcomes research : CEOR.
[23] J. Borrás,et al. Psychosocial oncology care resources in Europe: a study under the European Partnership for Action Against Cancer (EPAAC) , 2017, Psycho-oncology.
[24] J. Sfakianos,et al. Unmet informational and supportive care needs of patients following cystectomy for bladder cancer based on age, sex, and treatment choices. , 2016, Urologic oncology.
[25] F. Perrone,et al. Le dolenti note. La tossicità finanziaria del paziente oncologico , 2016 .
[26] C. la Vecchia,et al. The Role of Tobacco Smoke in Bladder and Kidney Carcinogenesis: A Comparison of Exposures and Meta-analysis of Incidence and Mortality Risks. , 2016, European urology.
[27] L. Kiemeney,et al. Low awareness of risk factors among bladder cancer survivors: New evidence and a literature overview. , 2016, European journal of cancer.
[28] J. Witjes,et al. Economic Burden of Bladder Cancer Across the European Union. , 2016, European urology.
[29] Peter C Gøtzsche,et al. Screening with urinary dipsticks for reducing morbidity and mortality. , 2015, The Cochrane database of systematic reviews.
[30] M. Meng,et al. The natural history of symptoms and distress in patients and families following cystectomy for treatment of muscle invasive bladder cancer. , 2014, The Journal of urology.
[31] J. Borrás,et al. Policy statement on multidisciplinary cancer care. , 2014, European journal of cancer.
[32] G. Gethin,et al. Using an e-Delphi technique in achieving consensus across disciplines for developing best practice in day surgery in Ireland , 2014 .
[33] Ronald B. Moore,et al. Using the Delphi technique to improve clinical outcomes through the development of quality indicators in renal cell carcinoma. , 2013, Journal of oncology practice.
[34] T. Albreht,et al. Joint Action European Partnership for Action Against Cancer , 2012, Archives of Public Health.
[35] M. Somerfield,et al. American Society of Clinical Oncology Clinical Practice Guidelines: formal systematic review-based consensus methodology. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] E. Wallen,et al. A multidisciplinary approach to the management of urologic malignancies: does it influence diagnostic and treatment decisions? , 2011, Urologic oncology.
[37] T. H. van der Kwast,et al. Select screening in a specific high-risk population of patients suggests a stage migration toward detection of non-muscle-invasive bladder cancer. , 2011, European urology.
[38] N. Petrelli,et al. The organization of multidisciplinary care teams: modeling internal and external influences on cancer care quality. , 2010, Journal of the National Cancer Institute. Monographs.
[39] V. Lokeshwar,et al. Bladder tumor markers: from hematuria to molecular diagnostics – where do we stand? , 2008, Expert review of anticancer therapy.
[40] Guy E. Thwaites,et al. The Diagnosis and Management of Tuberculous Meningitis , 2002, Practical Neurology.
[41] G. William Walster,et al. A comparative study of differences in subjective likelihood estimates made by individuals, interacting groups, Delphi groups, and nominal groups☆ , 1973 .
[42] C. Aring,et al. A CRITICAL REVIEW , 1939, Journal of neurology and psychiatry.
[43] Guendalina Graffigna,et al. ENGAGEMENT: un nuovo modello di partecipazione in sanità , 2018 .
[44] The Cancer Genome Atlas Research Network,et al. Comprehensive molecular characterization of urothelial bladder carcinoma , 2014, Nature.
[45] Jacques Ferlay,et al. GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012 , 2013 .
[46] T. Albreht,et al. European Partnership for Action Against Cancer - EPAAC , 2011 .
[47] Serena Borgna,et al. EUROPEAN PARTNERSHIP , 2006 .
[48] S. Culine,et al. Pembrolizumab (pembro) versus investigator’s choice of paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial cancer (UC): 5-year follow-up from the phase 3 KEYNOTE-045 trial. , 2022, Journal of Clinical Oncology.
[49] J. Nicholl,et al. A systematic review of the evidence , 2022 .